Nasdaq
$36.50▼ 0.03%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $3.53BShares out 96.7M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
10- 6d agoClosed26.10.17 09:224Ownership#●●●
Xenon Pharmaceuticals Inc.
Kelly Thomas Patrick, an executive at Xenon Pharmaceuticals Inc., filed a Form 4 report regarding changes in beneficial ownership of securities as of October 15, 2026. This filing serves as a standard disclosure of executive equity transactions, though specific share counts or percentage changes were not detailed in the provided document summary.…more
$36.50-0.03%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.1Pre-market26.10.01 22:204Ownership
Xenon Pharmaceuticals Inc.
Insider Kelly Thomas Patrick of Xenon Pharmaceuticals reported a change in beneficial ownership of securities as of September 30, 2026. This filing is a standard Form 4 report disclosing changes in executive shareholdings.…more
$36.50-0.03%vs prev closeView filingShare - 10.1Pre-market26.10.01 22:194Ownership
Xenon Pharmaceuticals Inc.
Insider Ian Mortimer of Xenon Pharmaceuticals Inc. filed a Form 4 report regarding changes in beneficial ownership of securities as of September 30, 2026. This filing serves as a standard disclosure of insider transactions and changes in equity holdings.…more
$36.50-0.03%vs prev closeView filingShare
9 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.2After-hours26.10.03 05:01#●●●
Xenon Pharmaceuticals Grants Equity Inducements to New Employees
Xenon Pharmaceuticals announced the grant of 17,850 share options and 10,500 restricted share units to eight new non-officer employees. This equity award is a standard recruitment incentive and does not have a material impact on the company's financial position.…more
$36.50-0.03%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.1Regular26.10.02 01:24
●●●●●●●● ●●●●● ●●●●●●
Xenon Pharmaceuticals CEO Ian Mortimer and CFO Thomas Kelly acquired 30,000 and 15,000 shares of the company, respectively. This significant insider buying reflects management's confidence in the firm's future prospects.…more
$36.50-0.03%vs prev closeShareBenzinga - 9.21After-hours26.09.22 05:01
●●●●●●●● ●●●●● ●●●●●●
Xenon Pharmaceuticals announced its participation in the upcoming TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit. This event is an investor conference and does not contain material financial news affecting the stock price.…more
$36.50-0.03%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report